Skip to content

Author

A. Matsukawa

We have 8 of 370 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Development and External Validation of an Updated Nomogram Including Both MRI and Local PSMA PET/CT Information for the Prediction of Side-specific Extraprostatic Extension in Patients Treated with Radical Prostatectomy

Take Home Message A combined prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT)–magnetic resonance imaging (MRI) model improved extraprostatic extension prediction in development but showed similar performance to MRI in external validation. The added value of PSMA PET/CT a...

V. Sweere, A. B. Bruins Slot, J. Heetman et al. · 0 citations
Open access Sep 2026

SPRED2 Negatively Regulates CD8+ T Cell‐Mediated Antitumor Immunity in Breast Cancer

ABSTRACT Activation of the RAS/RAF/ERK pathway is crucial for adaptive immunity. Here, we provide evidence that Sprouty‐related EVH1 domain containing 2 (SPRED2), an endogenous inhibitor of this pathway, negatively regulates CD8+ T cell‐mediated antitumor immunity in breast cancer. In EO771 and 4T1 mouse models, Spred2...

M. Tian, Teizo Yoshimura, Kun Zhao et al. · 0 citations
Open access Oct 2026

Oncological Outcomes and Safety Profiles of Adjuvant Nivolumab in Muscle‐Invasive Urothelial Carcinoma

Perioperative immunotherapy has become the standard of care in patients with high‐risk muscle‐invasive urothelial carcinoma (MIUC). This study aimed to clarify oncological outcomes and safety profiles of adjuvant nivolumab therapy in MIUC, focusing on upper tract urothelial carcinoma (UTUC).

Satoshi Katayama, Tatsushi Kawada, K. Mori et al. · 1 citation
Open access Sep 2026

Prognostic Stratification in High‐Volume Metastatic Hormone‐Sensitive Prostate Cancer Treated With First‐Line Androgen Receptor Pathway Inhibitor–Based Combination Therapy

We aimed to stratify clinical risk among patients with high‐volume metastatic hormone‐sensitive prostate cancer (mHSPC) treated with first‐line androgen receptor pathway inhibitor (ARPI) plus androgen deprivation therapy (ADT).

Keiichiro Miyajima, T. Yanagisawa, Wataru Fukuokaya et al. · 0 citations
Open access Sep 2026

Direct Measurement and AI-based Inference Reveal Histological Section Thickness as a Variable Physical Property Accessible from Routine H&E Images.

It is demonstrated that histological section thickness is not merely a microtome setting but a variable, tissue-dependent, and AI-inferable physical property of routine H&E sections that represents an underrecognized preanalytical source of image variation and a potential target for AI-assisted, thickness-aware quality...

Masayoshi Fujisawa, Toshiaki Ohara, Yuto Shimada et al. · 0 citations
Open access Sep 2026

Perioperative Safety and Long‐Term Oncological Outcomes of En Bloc Resection of Bladder Tumor: A Multicenter Real‐World Study of 668 Patients

To evaluate perioperative safety, pathological outcomes, and oncological outcomes of en bloc resection of bladder tumor (ERBT) in a large multicenter real‐world cohort.

T. Yanagisawa, A. Matsukawa, K. Iwatani et al. · 0 citations
Review Open access Aug 2026

Diet and risk of bladder cancer: a systematic review of epidemiological evidence.

Available evidence does not support a strong or consistent association between dietary factors and bladder cancer (BC) risk, and patients should be informed that dietary modifications alone are unlikely to meaningfully alter their BC risk.

Keiichiro Miyajima, Marcin Miszczyk, Navid Roessler et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.